First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).

被引：0

作者：

Di Giacomo, Anna Maria

Santangelo, Federica

Amato, Giovanni

Simonetti, Elena

Graham, Jill

Lahn, Michael M. F.

Di Conza, Giusy

Hammett, Tracey

Zorrilla, Rebeca

Durini, Marco

Tan, Ziyang

Tadepally, Lakshmikanth

Brodin, Petter

Occhipinti, Mariaelena

Simonelli, Matteo

Carlo-Stella, Carmelo

Santoro, Armando

Spiliopoulou, Pavlina

Evans, T. R. Jeffry

Maio, Michele

机构：

[1] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy

[2] Azienda Osped Univ Senese, UOC Immunoterapia Oncolog, Siena, Italy

[3] Univ Siena, Siena, Italy

[4] Beatson Canc Ctr, Glasgow, Lanark, Scotland

[5] iOnctura SA, Geneva, Switzerland

[6] Covance Clin & Peri Approval Serv LTD, Milan, Italy

[7] Karolinska Inst, Stockholm, Sweden

[8] Karolinska Inst, Dept Womens & Childrens Hlth, Sci Life Lab, Solna, Sweden

[9] Radiomics, Liege, Belgium

[10] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[11] Humanitas Univ, Milan, Italy

[12] IRCCS Humanitas Res Hosp, Milan, Italy

[13] IRCCS Humanitas Res Hosp, Rozzano, Italy

[14] Princess Margaret Canc Ctr Canada, Toronto, ON, Canada

[15] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3110

引用

页数：1

共 50 条

[1] Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Di Giacomo, A. M.
Simonelli, M.
Santangelo, F.
Amato, G.
Simonetti, E.
Graham, J.
Lahn, M.
Di Conza, G.
Hammett, T.
Zorrilla, R.
Kaur, P.
Ziyang, T.
Lakshmikanth, T.
Brodin, P.
Occhipinti, M.
Carlo-Stella, C.
Santoro, A.
Spiliopoulou, P.
Evans, T. R. J.
Maio, M.
ANNALS OF ONCOLOGY, 2024, 35 : S500 - S500
[2] Roginolisib, an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kd) in patients with uveal melanoma and advanced cancers
Di Giacomo, Anna Maria
Simonelli, Matteo
Santangelo, Federica
Amato, Giovanni
Simonetti, Elena
Graham, Jill
Lahn, Michael M. F.
Di Conza, Giusy
Hammett, Tracey
Zorrilla, Rebeca
Durini, Marco
Tan, Ziyang
Tadepally, Lakshmikanth
Brodin, Petter
Occhipinti, Mariaelena
Carlo-Stella, Carmelo
Santoro, Armando
Spiliopoulou, Pavlina
Evans, T. R. Jeffry
Maio, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma
Di Giacomo, A. M.
Santangelo, F.
Amato, G.
Simonetti, E.
Graham, J.
Lahn, M.
Zorilla, R.
van der Veen, L.
Johnson, Z.
Pickering, C.
Marechal, E.
Blanco, J.
Blanco, J.
Durini, M.
Gufford, B.
Lakshmikanth, T.
Brodin, P.
Spiliopoulou, P.
Evans, T. R. J.
Maio, M.
ANNALS OF ONCOLOGY, 2021, 32 : S1438 - S1438
[4] Roginolisib a Highly Selective Allosteric Modulator of the Phosphoinositide 3-Kinase Delta (PI3Kδ) in Patients with Refractory/Relapsed Follicular Lymphoma
Carlo-Stella, Carmelo
Lahn, Michael
Hammett, Tracey
Kaur, Paramjit
Zorrilla, Rebeca
Di Conza, Giusy
van der Veen, Lars
Pickering, Catherine
Santoro, Armando
BLOOD, 2023, 142
[5] First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), and pharmacodynamic (PD) results.
Di Giacomo, Anna Maria
Santangelo, Federica
Amato, Giovanni
Simonetti, Elena
Graham, Jill
Lahn, Michael M. F.
Van der Veen, Lars Anders
Johnson, Zoe
Pickering, Catherine Anne
Durini, Marco
Tan, Ziyang
Tadepally, Lakshmikanth
Brodin, Petter
Occhipinti, Mariaelena
Simonelli, Matteo
Carlo-Stella, Carmelo
Santoro, Armando
Spiliopoulou, Pavlina
Evans, T. R. Jeffry
Maio, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Juric, Dejan
de Bono, Johann S.
LoRusso, Patricia M.
Nemunaitis, John
Heath, Elisabeth I.
Kwak, Eunice L.
Macarulla Mercade, Teresa
Geuna, Elena
de Miguel-Luken, Maria Jose
Patel, Chirag
Kuida, Keisuke
Sankoh, Serap
Westin, Eric H.
Zohren, Fabian
Shou, Yaping
Tabernero, Josep
CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5015 - 5023
[7] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Juric, Dejan
Krop, Ian
Ramanathan, Ramesh K.
Wilson, Timothy R.
Ware, Joseph A.
Bohorquez, Sandra M. Sanabria
Savage, Heidi M.
Sampath, Deepak
Salphati, Laurent
Lin, Ray S.
Jin, Huan
Parmar, Hema
Hsu, Jerry Y.
Von Hoff, Daniel D.
Baselga, Jose
CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
[8] A first-in-human phase I study of CYH33, a phosphatidylinositol 3-kinase (PI3K) α selective inhibitor, in patients with advanced solid tumors.
Wei, Xiao-Li
Xu, Rui-hua
Zhao, Hongyun
Zhang, Yang
Zou, Ben-Yan
Wang, Feng
Liu, Jihong
Wang, Zhiqiang
Qiu, Miao-Zhen
Yu, Qiuqiong
Liu, Yun
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
Moore, Kathleen N.
Varghese, Anna M.
Hyman, David Michael
Callies, Sophie
Lin, Ji
Wacheck, Volker
Pant, Shubham
Bauer, Todd Michael
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
Patnaik, A.
Appleman, L. J.
Mountz, J. M.
Ramanathan, R. K.
Beeram, M.
Tolcher, A. W.
Papadopoulos, K. P.
Lotze, M. T.
Petro, D. P.
Laymon, C.
Paige, L.
Rajagopalan, P.
Jeffers, M.
Roth, D.
Dubowy, R. L.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →